Abbreviation | Definition |
---|---|
BRAF | B-Raf proto-oncogene, serine/threonine kinase |
CA-125 | Cancer antigene 125 |
CI | Confidence interval |
CR | Complete response |
CTCAE | Common Terminology Criteria for Adverse Events |
ctDNA | circulating tumor DNA |
EGFR | Epidermal growth factor receptor |
EMA | European Medicines Agency |
ERBB2 | erb-b2 receptor tyrosine kinase 2 |
FDA | Food and Drug Administration |
FFPE | Formalin fixed paraffin embedded |
GCIG | Gynecological Cancer InterGroup |
GCP | Good Clinical Practice |
GOF | Gain of function |
IMP | Investigational medical product |
IMWG | International Myeloma Working Group |
IV | Intravenous |
KIT | Mast/stem cell growth factor receptor Kitq |
LVEF | Left ventricle ejection fraction |
MET | Hepatocyte growth factor receptor |
DN-MTB | Danish National Molecular Tumor Board |
OS | Overall survival |
PCWG3 | Prostate Cancer Working Group 3 |
PD | Progressive disease |
PFS | Progression free survival |
PR | Partial response |
PSA | Prostate specific antigene |
RANO | Response Assessment in Neuro-oncology Criteria |
RECIST | Response Evaluation Criteria in Solid Tumours |
SD | Stable disease |
TIA | Transient ischemic attack |
TMB | Tumor Mutational Burden |
WES | Whole exome sequencing |
WGS | Whole genome sequencing |